¡Ya estamos en ! Descubre más
618.47 USD
-10.13
1.61%
Al cierre Actualizado 16 oct, 4:00 p.m. EDT
Antes de la apertura del mercado
Después del cierre del mercado
618.47
0.00
0%
1 día
-1.61%
5 días
0.94%
1 mes
0.33%
3 meses
14.97%
6 meses
19.94%
En lo que va del año
8.31%
1 año
18.66%
5 años
232.83%
10 años
1,996.51%
 

Acerca de: Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Empleados: 6,500

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 70.6%
Neutral 29.4%
Negativo 0%
Positivo
Zacks Investment Research
hace 3 días
CON vs. MEDP: Which Stock Should Value Investors Buy Now?
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
CON vs. MEDP: Which Stock Should Value Investors Buy Now?
Neutral
Zacks Investment Research
hace 3 días
Medpace (MEDP) Dips More Than Broader Market: What You Should Know
In the latest trading session, Medpace (MEDP) closed at $609.89, marking a -1.64% move from the previous day.
Medpace (MEDP) Dips More Than Broader Market: What You Should Know
Positivo
Seeking Alpha
hace 4 días
Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One
Medpace Holdings is misunderstood due to its faster, cleaner backlog burn, which the market misinterprets as a growth ceiling rather than a quality upgrade. Q2 revenues rose 17.2% to $707.3M, with EBITDA margin improving beneath headline pass-through cost effects; guidance for FY26 was raised across revenue, EBITDA, and EPS. Customer prepayments fund operations and share buybacks, supporting EPS growth and providing a buffer against potential cash flow volatility as biotech funding rebounds.
Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One
Neutral
Zacks Investment Research
hace 10 días
Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors
Medpace (MEDP) concluded the recent trading session at $602.9, signifying a -2.84% move from its prior day's close.
Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors
Neutral
Zacks Investment Research
hace 17 días
Medpace (MEDP) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Medpace (MEDP) stood at $622.11, denoting a +1% move from the preceding trading day.
Medpace (MEDP) Rises As Market Takes a Dip: Key Facts
Neutral
Zacks Investment Research
hace 19 días
CON or MEDP: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
CON or MEDP: Which Is the Better Value Stock Right Now?
Neutral
Business Wire
hace 25 días
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Company will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended yo.
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
Positivo
Zacks Investment Research
hace 25 días
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
Medpace (MEDP) concluded the recent trading session at $624.2, signifying a +1.94% move from its prior day's close.
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
Neutral
Zacks Investment Research
el mes pasado
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Medpace (MEDP) closed at $595.41, marking a +1.34% move from the previous day.
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
Positivo
Zacks Investment Research
el mes pasado
CON vs. MEDP: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks is more attractive to value investors?
CON vs. MEDP: Which Stock Is the Better Value Option?
Gráficos de precios implementados con Lightweight Charts™